Table 1 Selected characteristics of the study population
Characteristic | Controls (n = 3,065) | Ductal cancer (n = 1,888) | Lobular cancer (n = 308) | Tubular cancer (n = 93) |
|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | No. (%) | |
Age (years) | ||||
50–54 | 233 (8) | 195 (10) | 31 (10) | 9 (10) |
55–59 | 582 (19) | 431 (23) | 70 (23) | 20 (22) |
60–64 | 678 (22) | 390 (21) | 61 (20) | 26 (28) |
65–69 | 790 (26) | 473 (25) | 73 (24) | 23 (25) |
70–74 | 782 (26) | 399 (21) | 73 (24) | 15 (16) |
Surgical menopause | ||||
Yes | 125 (4) | 85 (5) | 11 (4) | 5 (5) |
Unknown | 10 | 27 | 5 | 1 |
Menopausal symptoms | ||||
Yes | 1,469 (57) | 1,113 (60) | 186 (61) | 62 (67) |
Unknown | 477 | 29 | 2 | 1 |
Socioeconomic status | ||||
Blue collar worker | 830 (32) | 549 (29) | 93 (30) | 18 (20) |
White collar worker | 1,412 (54) | 1,081 (58) | 175 (57) | 60 (67) |
Other | 337 (14) | 248 (13) | 39 (13) | 12 (13) |
Unknown | 450 | 10 | 1 | 3 |
Ever use of menopausal hormone therapy | ||||
Any type | 1,185 (39) | 891 (47) | 170 (55) | 55 (59) |
Unknown | 24 | 5 | 1 | 0 |
Estrogen (+/- progestin) | 612 (20) | 533 (28) | 116 (38) | 40 (43) |
Estradiol | 506 (17) | 452 (24) | 100 (33) | 36 (39) |
Conjugated estrogens | 69 (2) | 80 (4) | 17 (6) | 5 (5) |
Other estrogens | 19 (0.6) | 17 (0.9) | 3 (1) | 1 (1) |
Administration of estrogen | ||||
Tablets | 526 (17) | 465 (25) | 103 (34) | 39 (42) |
Patches | 123 (4) | 114 (6) | 18 (6) | 4 (4) |
Injections | 20 (0.7) | 12 (0.6) | 1 (0.3) | 1 (1) |
Progestin (+/- estrogen) | 462 (15) | 420 (22) | 95 (31) | 38 (41) |
Progesterone derived progestin | 138 (5) | 126 (7) | 39 (13) | 9 (10) |
Testosterone derived progestin | 371 (12) | 353 (19) | 79 (26) | 35 (38) |
Low potency oral estrogen | 354 (12) | 224 (12) | 45 (15) | 9 (10) |
Local estrogen | 374 (12) | 260 (14) | 33 (11) | 12 (13) |